LZAGY - Lonza Group AG

Other OTC - Other OTC Delayed Price. Currency in USD
63.28
+0.71 (+1.14%)
At close: 03:46PM EDT
Stock chart is not supported by your current browser
Previous close62.57
Open63.25
Bid0.00 x 0
Ask0.00 x 0
Day's range63.00 - 63.38
52-week range43.85 - 65.96
Volume27,669
Avg. volume49,908
Market cap47.007B
Beta (5Y monthly)0.62
PE ratio (TTM)35.16
EPS (TTM)1.80
Earnings dateN/A
Forward dividend & yield0.39 (0.62%)
Ex-dividend date09 May 2023
1y target estN/A
  • Reuters

    European stocks fall on earnings jitters, rate hike worries

    (Reuters) -European stocks slipped on Wednesday as lacklustre results from U.S. software giant Microsoft fanned fears about the outlook for the tech sector, while investors remained concerned that central banks were not yet close to pausing their interest rate hikes. The pan-European STOXX 600 fell for a second day, closing down 0.3% but off a near two-week low hit earlier in the session. Technology shares, which have rebounded this year after a rough 2022, fell 0.4% as Microsoft forecast current-quarter cloud business revenue below estimates.

  • Reuters

    Lonza to buy back $2.17 billion worth of shares, backs mid-term growth

    (Reuters) -Lonza on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future. Lonza expects its 2023 core earnings before interest, depreciation and amortization, or EBITDA margin, to slip between 30% and 31%, down from 32.1% in 2022, as last year's boost from COVID-19 vaccine manufacturing services waned. The firm, which is in a multi-year investment push to assist drug developers as they bet on new therapeutic proteins, as well as cell and gene therapies, also reported an almost 20% jump in core 2022 EBITDA of 2.0 billion Swiss francs, slightly ahead of market expectations.

  • Reuters

    Lonza's first-half core EBITDA gains 16.5%

    (Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies. First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs. For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.